Women's Health

BRCA Gene May Predict Drug Resistance in Ovarian Cancer, Study Finds

What happened to cancer patients who didn't develop this second BRCA mutation?

When comparing survival in ovarian cancer patients with and without this loss of heterozygosity, there was a significant difference in life expectancy. It turns out that people without this second mutation have a much poorer response to platinum chemotherapies. When both groups were treated with the platinum drugs, those who still had one normal BRCA left lived a median of 39 months compared to the 71-month median experienced by the double-hit group.